SHANGHAI -- China's Clover Biopharmaceuticals is set to debut on the Stock Exchange of Hong Kong on Friday as it races to win regulatory approval and begin shipments of its COVID-19 vaccine.
IPO
Chinese COVID vaccine maker Clover Biopharma set for HKEX debut
Company aims to win regulatory approval and begin shipments to COVAX by year-end
Development of Clover's COVID vaccine was financed by a grant worth up to $360.5 million from CEPI. © Reuters
Read Next
Latest on IPO
